Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study

Cognition Therapeutics (CGTX) published results of a proteomics analysis from the Phase 2 ‘SEQUEL’ COG0202 Study of zervimesine in adults with mild-to-moderate Alzheimer’s disease. The manuscript, titled Identification of Cerebrospinal Fluid Pharmacodynamic Biomarkers and Molecular Correlates of Brain Activity in a Phase 2 Clinical Trial of the Alzheimer’s Disease Drug Candidate, CT1812, was published in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. In the SEQUEL study, zervimesine treatment resulted in consistent trends of improvement across all prespecified EEG parameters, including the prominence of certain EEG frequencies associated with Alzheimer’s disease. Slower frequencies termed “theta” waves were reduced after 29 days of zervimesine treatment compared to placebo. This suggests zervimesine may normalize the function of neurons and synapses.